Difference between revisions of "Part:BBa K1835501"
LiuWanTing (Talk | contribs) |
|||
| Line 5: | Line 5: | ||
Further research into the action of tachyplesin and protegrin revealed that in addition to having antimicrobial ability, both peptides also exhibited some degree of hemolytic activity against human erythrocytes. In the interest of safety, we wanted to find a way to get rid of the hemolytic activity without abolishing the antimicrobial action. Some more digging led us to research that had been done on versions of both of these antimicrobial peptides in which all cysteine residues had been removed. For tachyplesin, it was found that while the deletion of cysteines somewhat decreased the peptides antibiotic capacity, it completely got rid of its ability to lyse human red blood cells. Likewise, the deletion of cysteines in protegrin was found to have little effect on its ability to kill bacteria, however there was no investigation into its hemolytic activity. Based on this information, we decided to develop genes for these cysteine-deleted antimicrobial peptides and investigate them further. | Further research into the action of tachyplesin and protegrin revealed that in addition to having antimicrobial ability, both peptides also exhibited some degree of hemolytic activity against human erythrocytes. In the interest of safety, we wanted to find a way to get rid of the hemolytic activity without abolishing the antimicrobial action. Some more digging led us to research that had been done on versions of both of these antimicrobial peptides in which all cysteine residues had been removed. For tachyplesin, it was found that while the deletion of cysteines somewhat decreased the peptides antibiotic capacity, it completely got rid of its ability to lyse human red blood cells. Likewise, the deletion of cysteines in protegrin was found to have little effect on its ability to kill bacteria, however there was no investigation into its hemolytic activity. Based on this information, we decided to develop genes for these cysteine-deleted antimicrobial peptides and investigate them further. | ||
| − | |||
| − | |||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
| Line 20: | Line 18: | ||
<partinfo>BBa_K1835501 parameters</partinfo> | <partinfo>BBa_K1835501 parameters</partinfo> | ||
<!-- --> | <!-- --> | ||
| + | |||
| + | |||
| + | ==2020 SZPT-CHIAN== | ||
| + | ===Characterization=== | ||
| + | We used Tachyplesin I on Streptococcus mutans UA159 to test the antibacterial activity. Dilute the antimicrobial peptides to each experimental group. After culturing for 20 hours, scan the plate with a microplate reader at 490 nm. The MIC value of the antimicrobial peptide is determined to be calculated as the minimum mass concentration lower than 50% growth of the control well. Obtained 8μg/ml as the minimum inhibitory concentration of antimicrobial peptide against Streptococcus mutans. | ||
| + | |||
| + | [[File:T--SZPT-CHINA--TP-1.png|900px|thumb|center|Corresponding to the concentration of added peptide, the growth of S. mutans in the cup around Oxford inhibitory concentration range is suppressed, clear inhibition zone is formed, followed by measurement of the size of the inhibition zone, i.e. inhibitory effect obtained bad.]] | ||
Revision as of 08:47, 19 October 2020
Tachyplesin-I
Tachyplesin I (TP-I) is a cysteine-rich antimicrobial peptide derived from the hemocytes of horseshoe crabs. It is very similar in structure, sequence, and function to Protegrin-1, containing the same disulfide bridges and resulting beta-sheet secondary structure which allows it to form pores in the membrane. This antimicrobial peptide was the first gene that we designed. Similar to how St. Andrews created BBa_K117000, the gene sequence for TP-I was derived by translating the amino acid residues to their most common codon triplet, putting those triplets in order, and adding start and stop codons.
Further research into the action of tachyplesin and protegrin revealed that in addition to having antimicrobial ability, both peptides also exhibited some degree of hemolytic activity against human erythrocytes. In the interest of safety, we wanted to find a way to get rid of the hemolytic activity without abolishing the antimicrobial action. Some more digging led us to research that had been done on versions of both of these antimicrobial peptides in which all cysteine residues had been removed. For tachyplesin, it was found that while the deletion of cysteines somewhat decreased the peptides antibiotic capacity, it completely got rid of its ability to lyse human red blood cells. Likewise, the deletion of cysteines in protegrin was found to have little effect on its ability to kill bacteria, however there was no investigation into its hemolytic activity. Based on this information, we decided to develop genes for these cysteine-deleted antimicrobial peptides and investigate them further.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
2020 SZPT-CHIAN
Characterization
We used Tachyplesin I on Streptococcus mutans UA159 to test the antibacterial activity. Dilute the antimicrobial peptides to each experimental group. After culturing for 20 hours, scan the plate with a microplate reader at 490 nm. The MIC value of the antimicrobial peptide is determined to be calculated as the minimum mass concentration lower than 50% growth of the control well. Obtained 8μg/ml as the minimum inhibitory concentration of antimicrobial peptide against Streptococcus mutans.
